Bicara Therapeutics Inc. Common Stock

NASDAQ: BCAX · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0002023658Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 62DQ —GM —SS 51

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$137.9M

Employees

103

as of 2026-08-09

Market cap

$1.5B

as of 2026-08-09

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$137.9M-$137.9M2025

Operating income-$155.6M-$155.6M2025

Total assets$431.0M$431.0M2025

Liabilities$29.5M$29.5M2025

Equity$401.5M$401.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Bicara Therapeutics Inc. Common Stock’s financial profile?

Bicara Therapeutics Inc. Common Stock earned -$137.9M in FY2025 net income.

Peers · Healthcare

Damora Therapeutics, Inc.——Generate Biomedicines, Inc.——Tyra Biosciences, Inc.——First Tracks Biotherapeutics Inc——ArriVent BioPharma, Inc.——ORIC Pharmaceuticals, Inc.——

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M76B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B67B PTC Inc.$2.7B83B+

Key facts

CEOClaire Mazumdar Clemon

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: BCAX

Employees103

IPO date2024-09-13

Latest filings

8-K2026-08-25 10-Q2026-08-11 8-K2026-08-11 8-K2026-07-28 8-K2026-06-10 8-K2026-05-21 8-K2026-05-11 10-Q2026-05-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.